← Human Trials & Peer-Reviewed Studies
The effect of a hydrolyzed collagen-based supplement on wound healing in patients with burn: A randomized double-blind pilot clinical trial.
Plain-language guide to PMID 31859087 (2020): double-blind randomized controlled trial of Copper (Supplement) in 31 men.
Key Facts
- PMID
- 31859087
- Journal
- Burns : journal of the International Society for Burn Injuries
- Year
- 2020
- Study type
- Randomized Controlled Trial
- Authors
- Bagheri Miyab K et al. (7 authors)
- DOI
- 10.1016/j.burns.2019.02.015
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Copper (Supplement).
The aim of this study was to assess the effect of an oral, low-cost, and accessible collagen-based supplement on wound healing in patients with burn.
Who Took Part
The study group was 31 men.
By PubMed's age tags, the people studied were young adults, adults and middle-aged adults, men only.
How the Study Was Run
The design is described as randomized, double-blind, placebo-controlled and pilot.
The men were allocated by chance, so the Copper (Supplement) group and the comparison group should start out alike.
Neither the men nor the staff measuring them knew who was on Copper (Supplement), so expectations could not easily colour the readings.
The comparison arm used a placebo, so changes seen with Copper (Supplement) could be set against what happens without it.
It is described as a pilot, a small early test of whether a larger Copper (Supplement) study would be practical.
Serum pre-albumin, rate of wound healing, length of hospital stay, and anthropometries were assessed at baseline, and the end of week 2 and 4.
What Was Measured
The subject headings attached to it are Burns, Collagen, Dietary Sugars, Dietary Supplements, Gelatin, Length of Stay and Pilot Projects.
The authors tagged it with the keywords Hospital stay, Pre-albumin and Wound healing.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement) in 31 men.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2020 (Burns : journal of the International Society for Burn Injuries), a journal based in Netherlands.
More context: the Copper (Supplement) compound page, all human trials.
Our Notes on the Compound
Copper (Supplement): The active site of cytochrome c oxidase is described as containing copper ions that are essential for electron transfer.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.